Estrella Immunopharma (ESLA) said Friday it has completed the first dose group in its ongoing phase I/II clinical trial evaluating EB103 in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Based on preliminary data, no dose-limiting toxicities or serious adverse events related to treatment were observed in the group, with tumor response noted in all patients in the first month, the company said.
After reviewing safety and efficacy data, the Data and Safety Monitoring Board has approved the initiation of a higher dose group, the company added.
The company's shares were up 4% in recent trading.
Price: 1.55, Change: +0.06, Percent Change: +4.03
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。